Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics Gets Non-Exclusive License To Japanese Stem Cell Portfolio

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The stem cell technologies company Cellular Dynamics International announced today that it has entered into a non-exclusive licensing agreement with iPS Academia Japan, giving it access to a patented induced pluripotent stem cell portfolio based on research by Shinya Yamanaka at Kyoto University's Center for iPS Cell Research and Application.

Under the agreement, CDI will provide iPS Academia Japan with "considerations" and running royalties. The move makes CDI the only non-Japanese company to date to hold a license to the Kyoto University iPSC patent portfolio.

CDI, which was founded in 2004, also holds a license to iPSC technology stemming from work by University of Wisconsin at Madison stem cell researcher James Thomson, the company's founder and chief scientific officer.

"Stem cells have such great potential — to find the root cause of disease, to test new drugs at the human cellular level, and to eventually impact individual healthcare," CDI's Thomson said in a statement. "This agreement sets the stage for a partnership that will foster collaboration to move our technology forward."

Last year the company licensed intellectual property from Indiana University-Purdue University Indianapolis for stem cell purification and drug testing methods and from the Mount Sinai School of Medicine related to human cardiovascular progenitor cells.

CDI launched a commercial line of iPSC-derived human heart cells, called iCell Cardiomyocytes, last year. Within the next 12 to 18 months the company also intends to release other cell types developed using similar stem cell methods, including liver, neural, and blood vessel cells.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.